The second generation of selective anti-IL-23 therapies targets IL-23p19, and they have demonstrated greater effectiveness compared to ustekinumab in treating other immune-mediated conditions, such as plaque psoriasis, prompting us to explore their potential use in IBD [19,20]. This evidence concerns the gene IL23A and inflammatory bowel disease.